Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Hypertension
Interventions: valsartan+amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Cognitive Impairment, Mild, Depressive Symptoms, Anxiety
Interventions: Active Transcranial Direct Current Stimulation (tDCS), Sham Transcranial Direct Current Stimulation (tDCS); Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: Psoriatic Arthritis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 33
States / cities: Gilbert, Arizona • Jonesboro, Arkansas • Fontana, California + 30 more

Conditions: Bipolar Disorder
Interventions: Galantamine, Placebos; Drug
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Postpartum Depression
Interventions: WB001, ED001; Device
Lead sponsor: Woebot Health; Industry
Eligibility: 22 Years to 45 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Lafayette, California • Santa Ana, California • DeLand, Florida + 5 more

Conditions: Parkinson Disease, Multiple System Atrophy, REM Sleep Behavior Disorder, Pure Autonomic Failure, Dementia With Lewy Bodies
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyponatremia
Interventions: YM087; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 27
States / cities: Mobile, Alabama • Phoenix, Arizona • Tuscon, Arizona + 24 more

Conditions: Bronchiectasis
Interventions: BI 1291583, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Peoria, Arizona • Newport Beach, California • Sacramento, California + 12 more

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream, Placebo of Pimecrolimus Cream, 1%; Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 12 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 27
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more

Conditions: Alopecia Areata
Interventions: CTP-543, CTP-543 matching placebo; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 13
States / cities: Irvine, California • Rancho Mirage, California • Redwood City, California + 10 more

Conditions: Smoking
Interventions: mTHS 2.2, mCC, NNS; Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Rosacea
Interventions: Doxycycline, Placebo; Drug · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Hot Springs, Arkansas • San Diego, California • Evansville, Indiana + 7 more

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 64
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more

Conditions: Stress Disorders, Post-Traumatic
Interventions: EFT (Emotional Freedom Techniques); Behavioral
Lead sponsor: Soul Medicine Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Santa Rosa, California

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions: Fecal Microbiota Transplant (FMT), Placebo; Biological
Lead sponsor: Stacy A. Kahn; Other
Eligibility: 5 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions: ACULAR, REFRESH TEARS, placebo; Drug
Lead sponsor: University of South Alabama; Other
Eligibility: 10 Days to 15 Days
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: AEBT Website With Check-ins, AEBT Website Without Check-ins
Interventions: Acceptance-Enhanced Behavior Therapy; Behavioral
Lead sponsor: Utah State University; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Hepatocellular Carcinoma
Interventions: Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE); Drug · Other · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 24
States / cities: Costa Mesa, California • La Jolla, California • Orange, California + 19 more

Conditions: Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2
Interventions: Insulin glargine, insulin NPH; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Heart Failure With Reduced Ejection Fraction, HIV Infections
Interventions: Heart failure polypill, Control Rx; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bipolar Disorder
Interventions: MCN36 (nutritional supplement), Placebo; Drug
Lead sponsor: University of Calgary; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Developmental Language Disorder and Language Impairment
Interventions: Recast Therapy, Syntax Stories; Behavioral
Lead sponsor: University of Delaware; Other
Eligibility: 4 Years to 9 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Newark, Delaware • College Park, Maryland

Conditions: Child Obesity, Cardiometabolic Health
Interventions: Brighter Bites; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 6 Years to 9 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Major Depressive Disorder
Interventions: vilazodone, placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Newport Beach, California • Bradenton, Florida • Atlanta, Georgia + 6 more

Search by objective public record fields.

One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension

Brain Stimulation and Enhancing Cognition in Older Adults

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder

[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]

Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease

Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)

Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Gene Expression Correlates of Post-Traumatic Stress Disorder (PTSD) Symptom Change After EFT (Emotional Freedom Techniques)

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

A RCT of a Fully-automated Self-help AEBT Website

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

RCT Glargine vs NPH for Treatment of DM in Pregnancy

Heart Failure Polypill at a Safety Net Hospital

Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder

Recasting or Book Reading by Parents or Clinicians

Evaluating the Impact of a School-based Fruit and Vegetable Co-op on Cardiometabolic Child and Parents Health in a Persistent Poverty Area

Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)